Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: A more prominent role for oophorectomy

Journal of Clinical Oncology

Volumn 20, Issue 8, 2002, Pages 2092-2100

  Van Roosmalen, Mariëlle S ^a   Verhoef, Lia C G ^a   Stalmeier, Peep F M ^a   Hoogerbrugge, Nicoline ^a   Van Daal, Willem A J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; DECISION MAKING; FEMALE; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; MASTECTOMY; ONCOGENE; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; BREAST NEOPLASMS; DECISION SUPPORT TECHNIQUES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC SCREENING; HUMANS; MARKOV CHAINS; MASTECTOMY; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; QUALITY-ADJUSTED LIFE YEARS;

EID: 0037089636     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.035     Document Type: Article

References (69)

1. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA 1
2. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer
3. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence
4. The genetic attributable risk of breast and ovarian cancer
5. The Breast Cancer Linkage Consortium: Breast and ovarian cancer incidence in BRCA1-mutation carriers
6. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
7. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
8. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2
9. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation
10. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer
11. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
12. Reduction in breast cancer risk following bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
13. Prophylactic oophorectomy
14. Breast cancer risk associated with gynecologic surgery and indications for such surgery
15. Postmenopausal estrogen therapy and cardiovascular disease; ten-year follow-up from the Nurses' Health Study
16. Hormone replacement therapy and risk of hip fracture: Population based case-control study - The Swedish Hip Fracture Study Group
17. Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture: Swedish Hip Fracture Study Group
18. Psychological impact of prophylactic oophorectomy in women at increased risk for ovarian cancer
19. Decision analysis: Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations
20. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: A decision analysis
21. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA-1 positive or BRCA- 2 positive patients
22. Benefits and costs of screening Ashkenazi Jewish women for BRCA 1 and BRCA2
23. Prevention with Tamoxifen or other hormones versus prophylactic surgery in BRCA 1/2-positive women: A decision analysis
24. Markov models in medical decision making: A practical guide
25. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
26. Bilateral prophylactic mastectomy (PM) in BRCA1/2 mutation carriers
27. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA 1 or BRCA2 mutation
28. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: A report of the Gilda Radner Familial Ovarian Cancer Registry
29. Ovarian cancer risk reduction after bilateral prophylactic oophorectomy (BPO) in BRCA1 and BRCA2 mutation carriers
30. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 1313 Randomized trials involving 31,000 recurrences and 29,000 deaths among 75,000 women
31. Immnunophenotypic and pathologic differences between BRCAI and BRCA2 hereditary breast cancers
32. Clinico-pathological characteristics of BRCA-1 or BRCA-2 related breast cancer
33. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA 1
34. Familial invasive breast cancers: Worse outcome related to BRCA 1 mutations
35. Current policies for surveillance and management in women at risk for breast and ovarian cancer: A survey among 16 European Family Cancer Clinics
36. The breast Surgeons role in BRCA 1 and BRCA2 testing
37. Effectiveness of breast surveillance in BRCA1/ 2 gene mutation carriers and women with high familial risk
38. Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden
39. BRCA-associated breast cancer in young women
40. Survival after breast cancer in Ashkenazi Jewish BRCA 1 and BRCA2 mutation carriers
41. Survival and tumor characteristics of German hereditary breast cancer patients
42. Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer
43. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA 1/2 breast cancer families
44. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA 1
45. Papillary serous carcinoma of the peritoneum
46. Papillary serous carcinoma of the peritoneum: A review of 33 cases treated with platin-based chemotherapy
47. Ovarian involvement by serous surface papillary carcinoma
48. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations
49. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer
50. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study
51. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
52. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
53. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomized women
54. Tamoxifen and breast cancer incidence among woman with inherited mutations in BRCA1 and BRCA2: A genomic resequencing study in the NSABP-P1 Breast Cancer Prevention Trial
55. Prophylactic oophorectomy in inherited breast/ovarian cancer families
56. Ovarian cancer risk reduction after bilateral prophylactic oophorectomy (BPO) in BRCA1 and BRCA2 mutation carriers
57. Survival in hereditary breast cancer associated with germline mutations of the BRCA 2
58. Efficacy of screening mammography: A meta-analysis
59. Efficacy of early diagnosis and treatment in women with a family history of breast cancer
60. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk
61. Magnetic resonance imaging in women with a hereditary risk of breast cancer
62. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer
63. Long-term satisfactionand psychological and social function following bilateral mastectomy